ALK and non-small cell lung carcinoma: We reported the cost-effectiveness of camrelizumab plus chemotherapy compared with chemotherapy alone in first-line treatment of patients with metastatic or advanced non-squamous NSCLC without targetable EGFR or ALK genetic aberrations in China.